162 related articles for article (PubMed ID: 24695996)
21. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
Cáceres-Redondo MT; Carrillo F; Lama MJ; Huertas-Fernández I; Vargas-González L; Carballo M; Mir P
J Neurol; 2014 Mar; 261(3):561-9. PubMed ID: 24477490
[TBL] [Abstract][Full Text] [Related]
22. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
Kim HJ; Park SY; Cho YJ; Hong KS; Cho JY; Seo SY; Lee DH; Jeon BS
J Neurol Sci; 2009 Dec; 287(1-2):200-4. PubMed ID: 19700173
[TBL] [Abstract][Full Text] [Related]
23. Cognitive impairments in advanced PD without dementia.
Green J; McDonald WM; Vitek JL; Evatt M; Freeman A; Haber M; Bakay RA; Triche S; Sirockman B; DeLong MR
Neurology; 2002 Nov; 59(9):1320-4. PubMed ID: 12427877
[TBL] [Abstract][Full Text] [Related]
24. Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review.
Alzahrani H; Venneri A
J Neurol Sci; 2015 Sep; 356(1-2):32-44. PubMed ID: 26123201
[TBL] [Abstract][Full Text] [Related]
25. Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function.
Ng A; Chander RJ; Tan LC; Kandiah N
Parkinsonism Relat Disord; 2015 Sep; 21(9):1056-60. PubMed ID: 26117438
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal changes in cognition in Parkinson's disease with and without dementia.
Johnson DK; Galvin JE
Dement Geriatr Cogn Disord; 2011; 31(2):98-108. PubMed ID: 21242691
[TBL] [Abstract][Full Text] [Related]
27. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
[TBL] [Abstract][Full Text] [Related]
28. Deep brain stimulation and cognitive functions in Parkinson's disease: A three-year controlled study.
Zangaglia R; Pacchetti C; Pasotti C; Mancini F; Servello D; Sinforiani E; Cristina S; Sassi M; Nappi G
Mov Disord; 2009 Aug; 24(11):1621-8. PubMed ID: 19514093
[TBL] [Abstract][Full Text] [Related]
29. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.
Connolly B; Fox SH
Neurotherapeutics; 2014 Jan; 11(1):78-91. PubMed ID: 24288035
[TBL] [Abstract][Full Text] [Related]
30. Improvement in Language Function Correlates with Gait Improvement in Drug-naïve Parkinson's Disease Patients Taking Dopaminergic Medication.
Murakami H; Momma Y; Nohara T; Mori Y; Futamura A; Sugita T; Ishigaki S; Katoh H; Kezuka M; Ono K; Miller MW; Kawamura M
J Parkinsons Dis; 2016; 6(1):209-17. PubMed ID: 26889633
[TBL] [Abstract][Full Text] [Related]
31. Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study.
Santangelo G; Vitale C; Trojano L; Picillo M; Moccia M; Pisano G; Pezzella D; Cuoco S; Erro R; Longo K; Pellecchia MT; Amboni M; De Rosa A; De Michele G; Barone P
Eur J Neurol; 2015 Feb; 22(2):253-60. PubMed ID: 24848193
[TBL] [Abstract][Full Text] [Related]
32. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
Arnaldi D; De Carli F; Famà F; Brugnolo A; Girtler N; Picco A; Pardini M; Accardo J; Proietti L; Massa F; Bauckneht M; Morbelli S; Sambuceti G; Nobili F
Mov Disord; 2017 Dec; 32(12):1738-1747. PubMed ID: 29119593
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease.
Caviness JN; Hentz JG; Belden CM; Shill HA; Driver-Dunckley ED; Sabbagh MN; Powell JJ; Adler CH
J Parkinsons Dis; 2015; 5(1):117-24. PubMed ID: 25420672
[TBL] [Abstract][Full Text] [Related]
34. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L
J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358
[TBL] [Abstract][Full Text] [Related]
35. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants.
Fasano A; Romito LM; Daniele A; Piano C; Zinno M; Bentivoglio AR; Albanese A
Brain; 2010 Sep; 133(9):2664-76. PubMed ID: 20802207
[TBL] [Abstract][Full Text] [Related]
36. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Schneider JS; Elm JJ; Parashos SA; Ravina BM; Galpern WR;
Parkinsonism Relat Disord; 2010 Sep; 16(8):507-12. PubMed ID: 20598621
[TBL] [Abstract][Full Text] [Related]
37. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.
Solla P; Cannas A; Ibba FC; Loi F; Corona M; Orofino G; Marrosu MG; Marrosu F
J Neurol Sci; 2012 Dec; 323(1-2):33-9. PubMed ID: 22935408
[TBL] [Abstract][Full Text] [Related]
38. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease.
Daniele A; Albanese A; Contarino MF; Zinzi P; Barbier A; Gasparini F; Romito LM; Bentivoglio AR; Scerrati M
J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):175-82. PubMed ID: 12531943
[TBL] [Abstract][Full Text] [Related]
39. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).
Riedel O; Klotsche J; Spottke A; Deuschl G; Förstl H; Henn F; Heuser I; Oertel W; Reichmann H; Riederer P; Trenkwalder C; Dodel R; Wittchen HU
J Neurol; 2008 Feb; 255(2):255-64. PubMed ID: 18204803
[TBL] [Abstract][Full Text] [Related]
40. The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease.
Poletti M; Frosini D; Pagni C; Baldacci F; Giuntini M; Mazzucchi S; Tognoni G; Lucetti C; Del Dotto P; Ceravolo R; Bonuccelli U
J Clin Exp Neuropsychol; 2013; 35(2):124-31. PubMed ID: 23216295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
